Skip to content
AnalystLens

MDT · Medtronic plc

140 filings

8-K

MDT 8-K Current Reports

Medtronic plc - 140 current reports

Filing record · 2016–202610-K1110-Q328-K120

MDT filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 120 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’17Mar ’17
  2. Material agreement8-K · Jul ’19Jul ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25
Showing 1-50 of 140 filings
8-K
Leadership ChangesShareholder MattersRegulation FD+1

Medtronic plc 8-K Report, Executive Changes (Oct 19, 2026)

Medtronic plc (MDT) filed an 8-K on October 19, 2026, detailing significant corporate governance and strategic updates. The report announces the appointment of Michael Marinaro to the newly expanded role of President, Medtronic, effective October 14, 2026. This promotion includes increased responsibilities, such as oversight of Greater China operations, and is accompanied by a substantial compensation package, reflecting his expanded influence within the company. The filing also confirms the successful completion of Medtronic's separation from MiniMed Group, Inc., finalized on October 15, 2026, through an exchange offer. Furthermore, the 8-K provides the voting results from Medtronic's Annual General Meeting held on October 15, 2026. Key outcomes include the re-election of all twelve director nominees, ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2027, and shareholder approval for executive compensation. The meeting also saw shareholders renew the Board's authority to issue shares and opt out of pre-emption rights, as well as authorize overseas market purchases of Medtronic ordinary shares. These developments signal both leadership continuity and strategic repositioning for Medtronic.

Oct 19, 20268-K
Other EventsExhibits & Filings

Medtronic plc 8-K Report, Corporate Update (Sep 17, 2026)

Medtronic plc (MDT) filed an 8-K on September 17, 2026, to provide an important correction to its previously filed Prospectus related to the ongoing offer to exchange outstanding Medtronic ordinary shares for newly issued common stock of its subsidiary, MiniMed Group, Inc. The primary purpose of this filing is to correct a typographical error concerning the expiration time of the guaranteed delivery procedures for tendering Medtronic shares in the exchange offer. This correction clarifies that the period for guaranteed delivery expires at 5:00 p.m. New York City time on the second NYSE trading day after the notice of guaranteed delivery is executed, rather than midnight as initially stated. This amendment ensures accurate communication to investors participating in the exchange offer, which allows them to tender Medtronic ordinary shares for up to 225,361,295 shares of MiniMed common stock. While the core terms of the exchange offer remain unchanged, this clarification is crucial for potential participants to properly execute their tender decisions within the specified timelines. Investors are strongly encouraged to review the corrected Prospectus and other relevant filings for complete details and to make informed decisions.

Sep 17, 20268-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Sep 1, 2026)

Medtronic plc (NYSE: MDT) reported first quarter fiscal 2027 results (quarter ended July 31, 2026) that beat its own guidance and led the company to raise full-year guidance. Reported and organic revenue each grew 13.7% to $9.756 billion, roughly 200 basis points above the guidance midpoint. GAAP diluted EPS was $1.14, up 40.7%, while non-GAAP diluted EPS was $1.45, up 15.1%. Management attributes the outperformance to breadth across the portfolio, not just one franchise. Cardiovascular grew 18.9% organically, led by 88% growth in Cardiac Ablation Solutions and 15% growth in Cardiac Rhythm Management. Neuroscience grew 9.3% and Medical Surgical grew 10.2%. Investors should weigh two points when reading the headline growth. First, the quarter included a 53rd (extra) week in the first fiscal month, which the company estimates added about $570 million, or roughly 6.6 points, to Q1 organic growth. Second, the company's FY27 guidance was raised modestly: organic revenue growth rises 50 basis points to 7.25%–7.75%, and non-GAAP EPS guidance moves to $5.94–$6.00 from $5.90–$6.00, with a neutral to 1% accretive currency benefit. The EPS raise is small relative to the revenue raise, so the implied margin or cost outlook is less changed than the top line. Other items of note include the Scientia Vascular and SPR Therapeutics acquisitions, which closed in the quarter, and the Pi-Cardia strategic investment. Free cash flow was $1.29 billion, up from $584 million a year earlier. The company also reiterated that the Diabetes separation is still in progress, with a split-off as the current preferred structure but no final decision yet. This 8-K furnishes the earnings press release under Item 2.02 and does not itself contain new financial statements or forward-looking commitments beyond the release.

Sep 1, 20268-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Jun 3, 2026)

Medtronic plc (MDT) reported fourth quarter and fiscal year 2026 results (year ended April 24, 2026), highlighting its strongest annual top-line growth in roughly a decade. FY26 revenue was $36.4 billion, up 8.4% as reported and 5.8% organic. Q4 revenue of $9.8 billion grew 9.9% reported and 6.6% organic, about 90 basis points ahead of implied guidance. Cardiovascular was the main driver, with Cardiac Ablation Solutions up 78% globally (124% in the U.S.) and Cardiac Rhythm & Heart Failure up high-teens organically, helped by Micra and the OmniaSecure launch. Medical Surgical grew 5.1% organically and Neuroscience grew 3.0%. Profitability was more mixed. Non-GAAP diluted EPS for FY26 was $5.53, up only 0.7% (down 2.0% in constant currency), and non-GAAP operating margin fell 130 basis points to 24.4%. Q4 non-GAAP EPS of $1.55 declined 4.3% year over year, with margin pressured by a 160 bp MiniMed Blackstone payment and 80 bp of tariffs. GAAP results were stronger, with Q4 GAAP diluted EPS of $0.96 up 17.1%, largely reflecting lower amortization and litigation charges and a favorable other non-operating item. Free cash flow was $5.4 billion, up 4.6%, and the company returned $4.2 billion to shareholders. Looking ahead, management guided FY27 organic revenue growth of 6.75% to 7.25% and non-GAAP diluted EPS of $5.90 to $6.00 (6.7% to 8.5% growth). The outlook includes a 53rd week, full-year consolidation of Diabetes (MiniMed), increased M&A, and tariff and interest headwinds. The board also raised the quarterly dividend to $0.72 (annualized $2.88), the 49th consecutive annual increase. The company continues to plan a separation of its Diabetes business, with an offering and split-off currently preferred but not finalized.

Jun 3, 20268-K
Leadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (May 18, 2026)

Medtronic plc (MDT) has filed an 8-K report on May 18, 2026, to announce a significant leadership transition within its Neuroscience Portfolio. Brett Wall is departing from his role as Executive Vice President and President, Neuroscience Portfolio. While he will remain with the company until September 1, 2026, to ensure a smooth handover, his departure marks a change in leadership for this key division. Dr. Kweli Thompson, currently Senior Vice President and President of Cardiac Rhythm Management, will assume the leadership of the Neuroscience Portfolio starting June 1, 2026. Investors should monitor the performance and strategic direction of the Neuroscience Portfolio under Dr. Thompson's leadership.

May 18, 20268-K
Regulation FDExhibits & Filings

Medtronic plc 8-K Report, Regulation FD Disclosure (Apr 27, 2026)

Medtronic plc (MDT) has disclosed a data security incident where an unauthorized third party accessed certain IT systems. The company identified the breach, took immediate containment measures, and engaged external cybersecurity experts to investigate. Based on the current investigation, Medtronic has not found any impact on its products, patient safety, customer relationships, manufacturing, distribution, or financial reporting. The company currently anticipates no material impact on its business or financial results from this incident. Investors should note that Medtronic has provided a statement on its website regarding this event, which is furnished as part of this 8-K filing. While the company has taken prompt action and currently assesses the impact as immaterial, ongoing monitoring and the full scope of the investigation will be crucial to watch for any potential future developments. The forward-looking statements disclaimer highlights inherent risks and uncertainties associated with such events.

Apr 27, 20268-K
Regulation FD

Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 24, 2026)

Medtronic plc (MDT) announced an important regulatory milestone for its consolidated subsidiary, MiniMed Group, Inc. The U.S. Food and Drug Administration (FDA) has granted clearance for the MiniMed Flex™, a next-generation insulin pump. This clearance arrived several months ahead of schedule, enabling an earlier commercial launch for this significant product in the diabetes management market. The development of the MiniMed Flex was partially funded by Blackstone, and under their agreement, Medtronic will incur a one-time charge of $157 million in the fourth quarter of fiscal year 2026, impacting reported EPS by approximately $0.08 per share. This charge relates to future payments to Blackstone based on sales performance during the initial two years post-launch. Additionally, the previously disclosed initial public offering (IPO) of 10% of MiniMed will contribute an additional $0.04 per share dilution to Medtronic shareholders in the fourth quarter of fiscal year 2026. Consequently, Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 downward to a range of $5.50 to $5.54, from the previous $5.62 to $5.66 range. The company's long-term outlook for fiscal year 2027, projecting high single-digit EPS growth, remains unchanged.

Mar 24, 20268-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Feb 17, 2026)

Medtronic (NYSE: MDT) reported third quarter fiscal 2026 results for the quarter ended January 23, 2026, with reported revenue of $9.017 billion, up 8.7% as reported and 6.0% organic, and 50 basis points ahead of its internal guidance. Growth was led by the Cardiovascular Portfolio, which rose 10.6% organically, driven by Cardiac Ablation Solutions (up 80%, including 137% in the U.S.) on the strength of its pulsed field ablation franchise. Cardiac Rhythm & Heart Failure grew high-teens organically, while Diabetes rose 8.3% organically. Neuroscience (+2.5% organic) and Medical Surgical (+2.7% organic) grew more modestly. Management described this as the highest enterprise revenue growth in 10 quarters. Profitability was mixed on a GAAP basis, with diluted EPS of $0.89 versus $1.01 a year earlier, reflecting higher operating costs, amortization, and restructuring charges. Non-GAAP diluted EPS was $1.36, versus $1.39 in the prior-year quarter, and was three cents above the guidance midpoint. Non-GAAP operating margin was 24.1%, compared with 26.2% a year earlier, and currency tailwinds of about $243 million boosted reported revenue. Medtronic reiterated its FY26 guidance of approximately 5.5% organic revenue growth and non-GAAP diluted EPS of $5.62 to $5.66, which includes an estimated $185 million tariff headwind. For investors, the key takeaways are the strength of the PFA-driven cardiovascular franchise, the reiterated full-year guidance despite a beat in the quarter, and the company's continued M&A activity, including the CathWorks and Anteris transactions. Margin compression and the GAAP-to-non-GAAP gap, which includes significant amortization, remain areas to monitor. Year-to-date free cash flow was $3.341 billion, up from $3.116 billion.

Feb 17, 20268-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Nov 18, 2025)

Medtronic reported fiscal Q2 2026 results (quarter ended October 24, 2025) that beat both revenue and EPS expectations, and the company raised its full-year FY26 guidance. Revenue was $8.96 billion, up 6.6% as reported and 5.5% organic, about 75 basis points above the guidance midpoint. GAAP diluted EPS was $1.07 (up 8%), and non-GAAP diluted EPS was $1.36 (up 8%), also ahead of guidance. Growth was led by the Cardiovascular portfolio (up 9.3% organic), with Cardiac Ablation Solutions revenue up 71% on pulsed field ablation (PFA) strength, including 128% growth in the U.S. FY26 guidance was raised to approximately 5.5% organic revenue growth (from about 5.0%) and to non-GAAP diluted EPS of $5.62 to $5.66 (from $5.60 to $5.66). The EPS range still includes an unchanged potential tariff impact of about $185 million. The company also highlighted regulatory and commercial milestones, including a broad CMS National Coverage Determination for the Symplicity renal denervation procedure, FDA approval of the Altaviva urge urinary incontinence device, and clearances for the MiniMed 780G system. Management said it expects revenue growth to accelerate in the second half of the year, while it stepped up R&D and sales and marketing investment. For investors, the key points are a beat-and-raise quarter driven by PFA and Cardiovascular strength, with the Neuroscience and Medical Surgical segments growing more slowly. Margin pressure is visible: non-GAAP operating margin fell 20 basis points to 24.1% as spending increased. Operating cash flow and free cash flow were modestly higher year to date. This filing is an 8-K furnishing the earnings press release under Item 2.02, so the financial information is unaudited.

Nov 18, 20258-K
Leadership Changes

Medtronic plc 8-K Report, Executive Changes (Nov 3, 2025)

Medtronic plc announced on November 2, 2025, that its Executive Vice President, Enterprise Operations, Gregory L. Smith, will retire from the company effective December 2, 2025. Mr. Smith's departure marks a leadership transition within the company's operations segment. Investors should note that his retirement triggers specific provisions regarding his outstanding equity compensation, as detailed in the company's filings.

Nov 3, 20258-K
Shareholder MattersCorporate ChangesExhibits & Filings

Medtronic plc 8-K Report, Bylaw Amendment (Oct 21, 2025)

Medtronic plc (MDT) filed an 8-K detailing the outcomes of its Annual General Meeting held on October 16, 2025. The primary focus of this report is the shareholder approval of significant amendments to the company's Articles of Association. These amendments, effective October 16, 2025, include modifications to Article 177 to enable the Board of Directors to capitalize non-distributable reserves for the creation of additional distributable reserves, and updates to the company's advance notice provisions for shareholder proposals. Beyond the governance-related changes, the meeting also saw shareholders overwhelmingly re-elect all twelve director nominees. Furthermore, investors ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026 and approved the compensation of named executive officers in advisory votes. The company also secured shareholder approval for renewing the Board's authority to issue shares and opt out of pre-emption rights, along with authorizing overseas market purchases of Medtronic ordinary shares. A capital reduction to create distributable reserves under Irish Law was also approved.

Oct 21, 20258-K
Material AgreementsOther EventsExhibits & Filings

Medtronic plc 8-K Report, Material Agreement (Sep 29, 2025)

Medtronic plc (MDT) has filed an 8-K report detailing a significant debt offering and the redemption of existing notes. On September 29, 2025, an indirect wholly owned subsidiary, Medtronic, Inc., successfully issued €1.5 billion in aggregate principal amount of senior notes, split between 2.950% Senior Notes due 2030 and 4.200% Senior Notes due 2045. These new notes are fully and unconditionally guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc. The primary purpose of this offering is to refinance existing debt. Medtronic, Inc. expects to use the net proceeds of approximately €1.49 billion to repay Medtronic Luxco's 0.000% Senior Notes due 2025 and its 2.625% Senior Notes due 2025. Concurrently, Medtronic Luxco has redeemed all outstanding €500 million of its 2.625% Senior Notes due 2025, with this redemption being contingent on the successful completion of the new notes issuance. This strategic debt management indicates Medtronic's effort to optimize its capital structure and extend its debt maturity profile.

Sep 29, 20258-K
Regulation FDOther EventsExhibits & Filings

Medtronic plc 8-K Report, Regulation FD Disclosure (Sep 16, 2025)

Medtronic plc (MDT) has filed an 8-K detailing the pricing and issuance of new senior notes, alongside the redemption of existing notes. The company will issue €1.5 billion in aggregate principal amount of new senior notes, consisting of €750 million due 2030 at 2.950% and €750 million due 2045 at 4.200%. These new notes are guaranteed by Medtronic plc and Medtronic Luxco. The net proceeds from this offering are earmarked to repay Medtronic Luxco's maturing 0.000% and 2.625% Senior Notes due 2025. Specifically, Medtronic Luxco has elected to redeem all outstanding €500 million of its 2.625% Senior Notes due 2025 on September 29, 2025, at a price of 100% of the principal plus accrued interest. The redemption is contingent on the successful completion of the new notes issuance. This refinancing activity was previously factored into Medtronic's reiterated fiscal year 2026 adjusted earnings per share guidance.

Sep 16, 20258-K
Earnings & ResultsLeadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Aug 19, 2025)

Medtronic reported first quarter fiscal 2026 results (quarter ended July 25, 2025) showing revenue of $8.578 billion, up 8.4% as reported and 4.8% organic, marking the 11th consecutive quarter of mid-single-digit organic growth. GAAP diluted EPS was $0.81 (up 1%) and non-GAAP diluted EPS was $1.26 (up 2%). Cardiac Ablation Solutions revenue grew nearly 50%, driven by pulsed field ablation, while Diabetes grew 7.9% organic. Management reiterated FY26 organic revenue growth guidance of approximately 5% and raised non-GAAP diluted EPS guidance to $5.60-$5.66 from $5.50-$5.60, reflecting a lower expected tariff impact of about $185 million. Non-GAAP operating margin declined 80 basis points to 23.6%, and free cash flow was $584 million versus $466 million a year earlier. The filing also discloses governance changes. The Board expanded from 11 to 13 directors, adding John Groetelaars and William Jellison, and formed two new committees, a Growth Committee and an Operating Committee, both chaired by CEO Geoff Martha. The company framed these steps as following constructive dialogue with activist investor Elliott Management, which the press release describes as having become one of Medtronic's largest investors. Medtronic also plans an Investor Day in mid-2026 and continues the planned separation of its Diabetes business (MiniMed). For investors, the key takeaways are the EPS guidance raise and the growth momentum in cardiac ablation, balanced against a slight margin decline and continued reliance on second-half acceleration to meet growth targets. The Elliott involvement and new committees signal heightened focus on portfolio simplification, margin improvement, and capital allocation.

Aug 19, 20258-K
Leadership Changes

Medtronic plc 8-K Report, Executive Changes (Jun 23, 2025)

Medtronic plc (NYSE: MDT) filed a Form 8-K on June 23, 2025 to disclose a board change. The Board increased its size from 10 to 11 members and appointed Dr. Joon Lee as an independent director, effective June 18, 2025. Dr. Lee is CEO of Emory Healthcare, Inc., an academic health system with roughly $7.7 billion in annual revenue, 12 hospitals, and more than 29,000 employees. He will serve on the Science and Technology Committee and the Compensation and Talent Committee. His background includes more than 25 years at UPMC, including roles as Executive Vice President and President of Physician Services and Chief Medical Officer of UPMC Insurance Services, plus a clinical background as an interventional cardiologist. For investors, this is a governance event rather than a financial one. The filing contains no earnings, guidance, or capital allocation information, and no material financial impact is disclosed. The appointment adds a healthcare-delivery and health-system executive to the board, which may be relevant to Medtronic's strategy around clinical data, digital health, and provider relationships. The filing also states that Dr. Lee has no undisclosed related-party transactions and no selection arrangements, which removes common governance concerns. Dr. Lee's compensation will follow the company's standard non-employee director policy, as described in the August 9, 2024 proxy statement. No new or unusual compensation arrangements are disclosed. Overall, the filing is routine board refreshment and should be viewed as low materiality for the stock, though it modestly strengthens the board's clinical and healthcare-operations expertise.

Jun 23, 20258-K
Earnings & ResultsLeadership ChangesOther Events+1

Medtronic plc 8-K Report, Financial Results (May 21, 2025)

Medtronic (NYSE: MDT) reported fourth quarter and fiscal year 2025 results for the year ended April 25, 2025, with FY25 reported revenue of $33.5 billion (up 3.6% reported, 4.9% organic) and Q4 revenue of $8.9 billion (up 3.9% reported, 5.4% organic). Profitability showed meaningful GAAP improvement, with FY25 GAAP diluted EPS of $3.61 (up 31%), but non-GAAP diluted EPS rose only 6% to $5.49, and non-GAAP operating margin expanded just 10 basis points (100 basis points on a constant currency basis). Free cash flow was $5.2 billion, flat year over year, and the company returned $6.3 billion to shareholders. Growth was led by Cardiac Ablation Solutions (pulsed field ablation), which grew nearly 30% in Q4 and reached $1.0 billion in FY25 revenue, along with Diabetes (up 10.7% reported in FY25) and Neuromodulation. Management guided FY26 organic revenue growth to approximately 5% and non-GAAP diluted EPS to $5.50 to $5.60 including potential tariff impacts, versus roughly 4% EPS growth excluding tariffs. The lower end of the range assumes US/China bilateral tariffs resume at higher rates after a 90-day pause. The board raised the quarterly dividend to $0.71 per share (annualized $2.84), marking the 48th consecutive annual increase. The company also announced its intent to separate the Diabetes business into a standalone public company, targeted within 18 months via an IPO followed by a split-off, which management expects to be accretive to gross margin, operating margin, and EPS. Leadership changed in Cardiovascular, with Skip Kiil succeeding Sean Salmon, who departs.

May 21, 20258-K
Leadership Changes

Medtronic plc 8-K Report, Executive Changes (Mar 17, 2025)

Medtronic plc (MDT) announced a leadership transition within its finance department. Jennifer M. Kirk, the Global Controller and Principal Accounting Officer, has resigned effective May 2, 2025, to pursue a CEO role at a private company, Exubrion Therapeutics. Investors should note that Ms. Kirk's departure is not attributed to any disagreements regarding Medtronic's operations or policies. To ensure a seamless handover, Denise L. Blomquist, currently the Assistant Global Controller, has been appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025. Ms. Blomquist brings extensive experience to the role, having been with Medtronic for 21 years in various finance positions. Her compensation will align with industry standards, including participation in the company's incentive and long-term incentive plans.

Mar 17, 20258-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Feb 18, 2025)

Medtronic plc reported third quarter fiscal 2025 results (quarter ended January 24, 2025) with worldwide revenue of $8.292 billion, up 2.5% as reported and 4.1% organic, marking the company's ninth consecutive quarter of mid-single-digit organic growth. GAAP diluted EPS was $1.01 (up 2%), while non-GAAP diluted EPS was $1.39 (up 7%), which management described as coming in above the high end of its guidance range. Gross margin expanded to 66.6% on a non-GAAP basis from 66.1%, and non-GAAP operating margin rose to 26.2% from 25.2%, indicating operating leverage on modest top-line growth. Growth was led by Cardiovascular (up 5.0% organic, with Cardiac Ablation Solutions up low-20s on pulsed field ablation products), Neuroscience (up 5.2% organic, with Neuromodulation up 12.9%), and Diabetes (up 10.4% organic). Medical Surgical was flat-to-down (down 0.4% organic) due to stapling pressures and a transient U.S. distributor buying pattern change. Management reiterated FY25 guidance: organic revenue growth of 4.75% to 5% and non-GAAP diluted EPS of $5.44 to $5.50, which includes an estimated 5% currency headwind. Reported revenue growth including Other revenue and FX is expected at 3.4% to 3.8%. The interim CFO, Gary Corona, said the company expects to accelerate both top- and bottom-line growth in Q4 and high-single-digit adjusted EPS growth in the second half of the fiscal year. The filing also disclosed a CMS National Coverage Analysis for renal denervation for hypertension, expected to be finalized by October 11, 2025, which could open a significant new market. For investors, the key items are the quality of the earnings beat, the margin expansion, and the reliance on a back-half acceleration to hit full-year targets. Free cash flow for the nine months rose to $3.116 billion from $2.849 billion, but the company also repurchased $2.961 billion of shares and issued $3.2 billion of long-term debt during the period. Total debt rose and current debt obligations increased to $2.622 billion, which investors may want to monitor alongside the buyback pace.

Feb 18, 20258-K
Leadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Jan 21, 2025)

Medtronic plc (NYSE: MDT) announced on January 21, 2025 that Thierry Piéton will become its Executive Vice President and Chief Financial Officer effective March 3, 2025, reporting to Chairman and CEO Geoff Martha and joining the Medtronic Executive Committee. Piéton most recently served as CFO of Renault Group (since March 2022), where management delivered its highest-ever operating margins and improved free cash flow. His background includes roughly 16 years at General Electric (including GE Healthcare), prior roles at Nissan, and an early career as an auditor at PricewaterhouseCoopers. He will lead global finance, including Treasury, Controller, Tax, Internal Audit, Investor Relations, Corporate Strategy, and Business Development. The compensation package is substantial and designed partly to offset forfeited awards at Renault. It includes an $850,000 base salary, a 110% target MIP bonus (prorated for FY2025), and an LTIP target of $2 million for FY2025, split among PSUs, options, and RSUs. He also receives a $3 million cash sign-on bonus paid in three installments, plus a $2.5 million new-hire RSU grant vesting in thirds beginning on the first anniversary. Severance eligibility under the Section 16 officer plan is contingent on termination without cause and a signed release. Separately, interim CFO Gary Corona received a one-time $1 million RSU grant, cliff-vesting after one year. Corona will remain with the company as Senior Vice President, Corporate Finance, and stays on the Executive Committee. For investors, the filing signals a planned transition to an experienced, operationally focused CFO after an interim period, with continuity provided by Corona. The filing does not disclose any change to financial guidance or results. The main points to watch are execution on the margin and cash flow priorities the company has emphasized, and whether Piéton's experience across regulated manufacturing and healthcare translates into the company's financial objectives.

Jan 21, 20258-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Nov 19, 2024)

Medtronic plc (NYSE: MDT) reported second quarter fiscal 2025 results for the quarter ended October 25, 2024, with revenue of $8.403 billion, up 5.3% as reported and 5.0% organic. Growth was broad-based across the Cardiovascular portfolio (+6.1% reported, +5.6% organic), led by Structural Heart & Aortic (high-single digit growth, supported by the U.S. launch of the Evolut FX+ TAVR system) and Cardiac Rhythm & Heart Failure (mid-single digit, with high-teens growth in Micra). Neuroscience grew 7.1% reported, with Neuromodulation up low-double digits and Diabetes up 12.4% reported and 11.0% organic. Medical Surgical was the weakest segment at +1.2% reported and +0.7% organic, with Surgical & Endoscopy flat organically. Cardiac Ablation Solutions was flat, as PulseSelect PFA growth offset cryoablation declines. Profitability is more mixed. GAAP diluted EPS rose 46% to $0.99, but this was flattered by lower income tax expense (effective tax rate of 18.0% versus 30.6% a year earlier, which included a prior-year tax charge). Non-GAAP diluted EPS was $1.26, up 1% as reported and 8% on a constant currency basis, with an approximately 9-cent currency headwind. Non-GAAP operating margin was 24.3%, versus 25.2% a year earlier. Management raised FY25 organic revenue growth guidance to 4.75%-5.0% (from 4.5%-5.0%) and non-GAAP EPS guidance to $5.44-$5.50 (from $5.42-$5.50), while noting an estimated 5% foreign currency headwind to EPS. Management expects high-single digit adjusted EPS growth in the second half of the fiscal year as currency effects abate. For investors, the key points are continued innovation-led growth in cardiovascular and neuromodulation, a narrowing EPS guidance range with a modest raise at the low end, and reliance on second-half margin recovery. Reported revenue including Other revenue and currency is guided at only 3.4%-3.9%, and the quarter included a $90 million Italian payback accrual in year-to-date results. Medtronic also disclosed a large share repurchase in the first half ($2.78 billion) and $3.2 billion of new long-term debt issuance. Gary Corona is serving as interim CFO.

Nov 19, 20248-K
Shareholder MattersExhibits & Filings

Medtronic plc 8-K Report, Shareholder Vote Results (Oct 21, 2024)

Medtronic plc (MDT) filed an 8-K on October 21, 2024, detailing the outcomes of its 2024 Annual General Meeting of Shareholders held on October 17, 2024. The meeting saw strong shareholder support for all proposals presented, indicating alignment between management and its investors on key corporate governance matters. All ten director nominees were elected, the appointment of PricewaterhouseCoopers LLP as the independent auditor for FY2025 was ratified, and executive compensation received advisory approval. Furthermore, shareholders renewed the Board's authority to issue shares, opt out of pre-emption rights, and to conduct overseas market purchases of Medtronic ordinary shares. The substantial 'FOR' votes across all resolutions, with a quorum of over a majority of outstanding shares present, underscores robust shareholder confidence and engagement.

Oct 21, 20248-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Aug 20, 2024)

Medtronic plc reported first quarter fiscal 2025 results (quarter ended July 26, 2024) that beat expectations on the top line and led management to raise its FY25 guidance. Reported revenue was $7.915 billion, up 2.8%, and organic growth was 5.3%, with Cardiovascular (+6.9% organic), Neuroscience (+5.3%) and Diabetes (+12.6%) leading. Medical Surgical was weaker at +1.0% organic. GAAP diluted EPS was $0.80, up 36%, but this is flattered by a $142 million Italian payback accrual and a tax-related swing: GAAP net income rose 32% while non-GAAP net income was flat at $1.592 billion. Non-GAAP diluted EPS was $1.23, up 3% (8% in constant currency), with a roughly 6-cent currency headwind. Management raised FY25 organic revenue growth guidance to 4.5%-5% (from 4%-5%) and non-GAAP diluted EPS guidance to $5.42-$5.50 (from $5.40-$5.50). Including Other revenue and currency, adjusted revenue growth is guided to 3.4%-4.3%, and EPS growth to 4%-6% after an estimated 5% currency headwind. Cash flow was softer: free cash flow fell to $466 million from $521 million as capital expenditures rose to $520 million, and the company repurchased $2.5 billion of shares while issuing $3.2 billion of long-term debt, which pushed long-term debt up to $26.3 billion. The company is led on an interim basis by CFO Gary Corona, which investors should note. For investors, the key takeaways are solid organic growth driven by new product launches (Evolut FX+, PulseSelect, Inceptiv, Percept RC, MiniMed 780G, Simplera), a modest guidance raise, and quality-of-earnings caveats: reported GAAP gains were partly driven by tax and non-operating items, and the Italian accrual is a one-time charge affecting Other revenue and the quarter's margins.

Aug 20, 20248-K/A
Leadership Changes

Medtronic plc 8-K/A Report, Executive Changes (Aug 16, 2024)

Medtronic plc (MDT) has filed an 8-K/A amendment to its previous filing, providing updated details on the compensatory arrangement for its interim Chief Financial Officer, Gary Corona. This amendment clarifies the financial incentives put in place following his appointment, which was previously announced. Investors should note the specific cash stipend and equity grant designed to compensate Mr. Corona during his interim role. The key takeaways for investors revolve around the financial terms of Mr. Corona's interim CFO position. These include a substantial bi-weekly cash stipend and a significant RSU grant, which are designed to incentivize and compensate him for taking on this critical role. While his base salary, target bonus, and existing long-term incentive grant remain unchanged, the new arrangements provide a clear picture of the additional compensation tied to his interim CFO responsibilities.

Aug 16, 20248-K
Leadership ChangesRegulation FDExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Jun 26, 2024)

Medtronic plc (NYSE: MDT) disclosed in this June 26, 2024 Form 8-K that Executive Vice President and Chief Financial Officer Karen Parkhill will resign effective August 2, 2024, to become CFO of HP Inc. Her departure is a leadership change at the finance function, and the filing does not indicate any disagreement with the company, which is a point investors often look for. Gary Corona, Senior Vice President of Global Financial Planning and Analysis since joining Medtronic in January 2023, will serve as interim CFO upon Parkhill's departure. Corona previously spent 26 years at General Mills, most recently as Vice President of Corporate Finance. His compensation is not changing in connection with the interim appointment. The company said it is evaluating both internal and external candidates for a permanent CFO, so a longer-term appointment remains open. Medtronic also reaffirmed its guidance for the first quarter and full fiscal year 2025, as previously disclosed in its May 23, 2024 earnings release. For investors, the key takeaways are the orderly transition, the reaffirmed outlook, and the open question of who will be permanent CFO. Parkhill had led the finance function for roughly eight years, and CEO Geoff Martha praised her contributions.

Jun 26, 20248-K
Leadership Changes

Medtronic plc 8-K Report, Executive Changes (Jun 4, 2024)

Medtronic plc (MDT) announced the retirement of Rob ten Hoedt, Executive Vice President and President of Global Regions, effective June 28, 2024. This departure marks a significant leadership change within the company's international operations. While the filing itself is brief, it signals the need for investors to monitor the transition process and the company's strategic adjustments in its global markets. Investors should pay close attention to any subsequent announcements regarding Mr. ten Hoedt's successor and the operational plans for the Global Regions segment moving forward.

Jun 4, 20248-K
Material AgreementsRegulation FDOther Events+1

Medtronic plc 8-K Report, Material Agreement (Jun 3, 2024)

Medtronic plc, through its indirect wholly owned subsidiary Medtronic, Inc., has successfully completed a significant debt offering, raising approximately €2.97 billion. This offering comprises four series of senior notes due in 2029, 2036, 2043, and 2053, with coupon rates ranging from 3.650% to 4.150%. These notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, providing an additional layer of credit support for investors. The net proceeds are intended for general corporate purposes, including the potential repayment of outstanding commercial paper and other existing indebtedness. This strategic move suggests Medtronic is actively managing its capital structure and may be refinancing existing debt, potentially at more favorable terms or extending its debt maturity profile. The company has applied to list these new notes on the New York Stock Exchange, enhancing their liquidity and accessibility for investors.

Jun 3, 20248-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (May 23, 2024)

Medtronic plc reported fourth-quarter and full-year fiscal 2024 results (FY24 ended April 26, 2024), with broad-based organic growth across all four segments. FY24 revenue was $32.4 billion, up 3.6% as reported and 5.2% organic. Q4 revenue was $8.6 billion, up 0.5% as reported and 5.4% organic, though reported growth was held back by a $265 million one-time IP agreement in the prior-year quarter and by business exits. Cardiovascular grew 5.0% organically for the year, Neuroscience 5.2%, Medical Surgical 4.7%, and Diabetes 8.6%, with Diabetes showing the strongest momentum. Profitability on a GAAP basis weakened sharply in Q4, with GAAP diluted EPS of $0.49 versus $0.88 a year earlier, driven largely by a $439 million charge tied to the decision to exit the ventilator product line and other acquisition-related items. Non-GAAP diluted EPS was $1.46 in Q4, down 7%, and $5.20 for the year, down 2% as reported but up 5% on a constant-currency basis, with a $0.33 currency headwind. Cash generation was strong: FY24 operating cash flow rose 12% to $6.8 billion and free cash flow rose 14% to $5.2 billion, helped by working-capital improvements. Management guided FY25 organic revenue growth to 4% to 5%, reported revenue growth to 2.4% to 3.7%, and non-GAAP diluted EPS to $5.40 to $5.50, which includes an estimated 5% currency headwind. The board also raised the quarterly dividend to $0.70 per share, marking the 47th consecutive annual increase.

May 23, 20248-K
Earnings & ResultsLeadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Feb 20, 2024)

Medtronic's Q3 FY24 (quarter ended January 26, 2024) showed steady top-line momentum. Revenue reached $8.089 billion, up 4.7% as reported and 4.6% organic, led by Diabetes (+10.2% organic), Structural Heart & Aortic (+9.6% organic), Core Spine, and Cardiac Pacing, with international markets strong. GAAP diluted EPS was $0.99 (up 8%), while non-GAAP diluted EPS of $1.30 was flat year over year, with an 11-cent (8%) currency headwind. Management raised FY24 guidance: organic revenue growth now 4.75% to 5% (from 4.75%), and non-GAAP EPS to $5.19–$5.21 (from $5.13–$5.19), a 4-cent midpoint increase. Reported FY24 revenue growth is guided to 2.9% to 3.3%, reflecting divestitures and currency. The most significant strategic news is the decision to exit the ventilator business and combine the remaining Patient Monitoring and Respiratory Interventions businesses into a single unit, Acute Care and Monitoring (ACM). Management characterized ventilators as increasingly unprofitable and expects existing manufacturers to meet market demand, while Medtronic will honor existing ventilator contracts. Ventilator sales already fell in the mid-twenties in the quarter. Separately, the 8-K discloses that Robert J. White, EVP and President of the Medical Surgical Portfolio, will leave on April 26, 2024, as his role is eliminated; his severance is a termination without cause under standard executive practices. Overall, the quarter shows solid revenue execution and cost discipline offsetting inflation, tax, and currency pressures, but flat non-GAAP EPS and the reported-growth gap keep the focus on whether product launches (PFA, Diabetes, Percept RC, Micra AV2/VR2) can drive reliable earnings growth.

Feb 20, 20248-K
Other Events

Medtronic plc 8-K Report, Corporate Update (Dec 6, 2023)

Medtronic plc (MDT) announced on December 6, 2023, that it has terminated its previously announced definitive agreements to acquire EOFlow Co. Ltd. The termination follows multiple alleged breaches of the agreements by EOFlow. Medtronic has stated that it does not believe any termination fee is payable under the terms of the agreements. This decision is significant as it halts a key strategic acquisition intended to bolster Medtronic's diabetes business. Importantly, Medtronic has clarified that this termination will not impact its previously issued fiscal year 2024 adjusted earnings per share guidance. The company remains committed to its automated insulin dosing product pipeline, including the development of a differentiated patch pump. Investors should note that this termination reflects Medtronic's disciplined approach to deal-making and its commitment to its strategic priorities, even when a transaction does not proceed as planned.

Dec 6, 20238-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Nov 21, 2023)

Medtronic plc (MDT) reported second quarter fiscal 2024 results (quarter ended October 27, 2023) showing solid, broad-based execution. Reported revenue was $7.98 billion, up 5.3% as reported and 5.0% organic, with growth across Cardiovascular (+4.8% organic), Neuroscience (+4.2% organic), Medical Surgical (+5.6% organic) and Diabetes (+6.7% organic). Management highlighted strength in Structural Heart (TAVR), Cardiac Pacing (Micra), Cranial & Spinal Technologies, and Surgical & Endoscopy (including Hugo robotic surgery installed base growth), along with new regulatory approvals such as the Aurora EV-ICD and Symplicity Spyral renal denervation system in the U.S. Profitability presents a mixed picture. GAAP diluted EPS was $0.68, up 113% year over year, but this was largely driven by a prior-year $764 million tax reserve charge that depressed the base period. On a non-GAAP basis, diluted EPS was $1.25, down 4% (including a 6% unfavorable currency impact of 8 cents), and non-GAAP net income declined 3%. Free cash flow for the first half of the fiscal year fell to $721 million from $1.256 billion, reflecting higher inventory and working capital outflows. Reported net sales are being affected by divestitures, including Renal Care Solutions and the Patient Monitoring and Respiratory Interventions separation, which are excluded from organic growth. Management raised FY24 guidance, now calling for organic revenue growth of 4.75% (up from 4.5%) and non-GAAP diluted EPS of $5.13 to $5.19 (up 4 cents at the midpoint). Reported revenue growth is estimated at approximately 2.6% including Other revenue and currency effects, and currency is expected to be a roughly 6% unfavorable headwind to EPS for the full year. The key investor debate is whether top-line momentum can translate into durable earnings growth given currency pressure, higher interest expense, and ongoing separation-related costs.

Nov 21, 20238-K
Leadership ChangesShareholder MattersExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Oct 23, 2023)

This 8-K filing from Medtronic plc details the outcomes of their 2023 Annual General Meeting of Shareholders held on October 19, 2023. The most significant news for investors is the shareholder approval of the Medtronic plc 2024 Employee Stock Purchase Plan (2024 Plan). This new plan will replace the existing 2014 Plan and makes available 30 million ordinary shares, with the first purchase period commencing January 1, 2024. Additionally, all director nominees were elected, the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024 was ratified, and executive compensation was approved on an advisory basis. The company also secured shareholder approval for the renewal of the Board's authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of its shares, which are important for strategic financial flexibility.

Oct 23, 20238-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Aug 22, 2023)

Medtronic plc (NYSE: MDT) reported first quarter fiscal 2024 results (quarter ended July 28, 2023) with revenue of $7.702 billion, up 4.5% as reported and 6.0% organically, with all four segments growing about 6% organically. Revenue strength was broad-based across Cardiovascular (up 6.2% organic, led by Structural Heart & Aortic at roughly 10.5% organic and mid-teens Micra growth), Neuroscience (up 5.6%), Medical Surgical (up 6.1%) and Diabetes (up 6.3%, with the MiniMed 780G launch driving strong non-U.S. growth, though U.S. Diabetes revenue declined 8.7%). Profitability was mixed: GAAP diluted EPS fell 16% to $0.59 on higher restructuring, litigation, and tax charges, while non-GAAP diluted EPS rose 6% to $1.20, including an 8 cent unfavorable currency impact that was 2 cents better than expected. Management raised FY24 guidance, lifting organic revenue growth to about 4.5% (from 4.0%-4.5%) and non-GAAP diluted EPS to $5.08-$5.16 (from $5.00-$5.10), a 7 cent increase at the midpoint. The company also said reported revenue growth would be roughly 2.75% at early-August exchange rates, reflecting currency headwinds and divestiture effects. Cash flow was weaker in the quarter, with operating cash flow of $875 million (down from $1.083 billion) and free cash flow of $521 million (down from $657 million), driven by working capital outflows including accounts payable and accrued liabilities. For investors, the key takeaways are the consistent mid-single-digit organic growth, the upward guidance revision, and the planned spinoff of the Patient Monitoring & Respiratory Interventions business targeted for the first half of fiscal 2025. Watch for free cash flow conversion, the GAAP-to-non-GAAP earnings gap driven by restructuring and litigation charges, and continued execution on the MiniMed 780G and Micra launches. Note that this 8-K furnishes the earnings press release (Exhibit 99.1) under Item 2.02 and that the figures are unaudited.

Aug 22, 20238-K
Leadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Jun 26, 2023)

Medtronic plc (NYSE: MDT) filed a Form 8-K on June 26, 2023 to disclose a board change: the Board increased its size from 11 to 12 members and appointed Greg Lewis as a new independent director, effective June 26, 2023. Lewis, currently Senior Vice President and Chief Financial Officer at Honeywell, will serve on the Audit Committee and the Finance and Financial Risk Committee. The filing states there were no arrangements or understandings under which he was selected, and no Item 404(a) related-person transactions involving him or his immediate family. From an investor standpoint, this is a routine governance event rather than a material operational or financial development. The appointment strengthens the board's financial oversight, given Lewis's extensive finance leadership experience across multiple industrial businesses at Honeywell, Tyco International, and the Stanley Works. Chairman and CEO Geoff Martha tied the appointment to Medtronic's ongoing 'comprehensive transformation' aimed at delivering durable growth, signaling that the board is adding expertise to support that effort. The filing contains no financial results, guidance, or quantitative disclosures. Lewis's director compensation will follow the company's existing non-employee director policy, as described in the August 19, 2022 proxy statement, so no new compensation arrangement is disclosed here. Investors should treat this as a modest governance update, with the transformation's progress more relevant to the stock than this board addition.

Jun 26, 20238-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (May 25, 2023)

Medtronic plc (NYSE: MDT) reported fiscal 2023 (ended April 28, 2023) results on May 25, 2023. Full-year worldwide revenue was $31.227 billion, down 1.4% as reported but up 2.1% organically, with a $1.437 billion currency headwind. Fourth-quarter revenue of $8.544 billion grew 5.6% both as reported and organically, ahead of expectations. However, that figure includes a one-time $265 million intellectual property payment from Edwards Lifesciences, so underlying growth was more modest. GAAP diluted EPS fell sharply, with Q4 at $0.88 (down 20%) and full-year at $2.82 (down 24%), largely reflecting restructuring, amortization, and one-time tax charges. Non-GAAP diluted EPS was $1.57 in Q4 (up 3%) and $5.29 for the year (down 5%). Full-year free cash flow fell 23% to $4.580 billion, equal to 65% conversion of non-GAAP net earnings. Management guided fiscal 2024 organic revenue growth of 4.0% to 4.5% and non-GAAP EPS of $5.00 to $5.10, including an estimated 6% currency headwind. Medtronic also raised its quarterly dividend to $0.69 per share ($2.76 annualized), marking its 46th consecutive annual increase, and reaffirmed a commitment to returning at least 50% of free cash flow to shareholders. The quarter showed broad-based momentum across Cardiovascular, Medical Surgical, Neuroscience, and Diabetes, supported by procedure recovery, improving supply, and new product launches such as the Affera mapping system and MiniMed 780G. Investors should weigh the strong dividend and recovering organic growth against the decline in GAAP earnings, currency pressure, and the one-time nature of the Q4 revenue boost.

May 25, 20238-K
Material AgreementsRegulation FDOther Events+1

Medtronic plc 8-K Report, Material Agreement (Mar 30, 2023)

Medtronic plc (MDT) announced on March 30, 2023, through its indirect wholly owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), the issuance of $2 billion in aggregate principal amount of senior notes. This offering comprises $1 billion of 4.250% Senior Notes due 2028 and $1 billion of 4.500% Senior Notes due 2033. The net proceeds, expected to be approximately $1.98 billion after expenses, are earmarked for the prepayment of a portion of Medtronic Luxco's Japanese-yen denominated term loan, which amounts to approximately $2.3 billion. This debt issuance represents a proactive move by Medtronic to refinance a specific tranche of its existing debt, likely to optimize its capital structure and potentially reduce interest expenses or alter its debt maturity profile. The notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc., providing additional security to investors. While the offering itself is not expected to have a material impact on interest expense, net, it signifies ongoing financial management and debt servicing strategies by the company.

Mar 30, 20238-K
Regulation FD

Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 9, 2023)

Medtronic plc (MDT) filed an 8-K on March 9, 2023, to address an erroneous communication regarding the redemption of its 0.000% Senior Notes due 2025, issued by its subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco"). The company clarified that Medtronic Luxco has not issued any notice of redemption for these notes. This disclosure was made to correct misinformation that had been erroneously communicated to data providers like Bloomberg and subsequently disseminated more widely. Investors should be aware that this filing is purely for informational purposes to correct a factual error and does not indicate any changes to Medtronic's debt obligations or financial strategy related to these specific notes.

Mar 9, 20238-K
Shareholder MattersOther Events

Medtronic plc 8-K Report, Shareholder Nominations (Mar 7, 2023)

This 8-K filing from Medtronic plc announces key dates and deadlines related to its 2023 Annual General Meeting of Shareholders (AGM). The AGM is scheduled for October 19, 2023, with a record date of August 25, 2023, for determining shareholders eligible to vote. This filing is crucial for investors as it sets the timelines for submitting shareholder proposals and director nominations. Notably, because the AGM date has shifted significantly from the previous year's anniversary, the previously announced deadlines for shareholder actions no longer apply. The company is providing updated timelines to ensure shareholders are aware of the requirements for presenting proposals or nominating directors, whether for inclusion in the proxy materials or for presentation directly at the meeting. Investors interested in actively participating in corporate governance through these avenues should pay close attention to the specified submission deadlines.

Mar 7, 20238-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Feb 21, 2023)

Medtronic plc reported fiscal Q3 2023 (quarter ended January 27, 2023) results that came in ahead of expectations at both the top and bottom line. Reported revenue was flat at $7.727 billion, but organic growth was 4.1%, a return to mid-single-digit growth. The headline reported figures were weighed down by a $379 million negative foreign currency impact and a $26 million contribution from the Intersect ENT acquisition, which is excluded from organic growth. GAAP diluted EPS fell 16% to $0.92, while non-GAAP diluted EPS fell 4% to $1.30. Management attributed the earnings decline mainly to unfavorable foreign currency translation and inflation. Growth was led by the Cardiovascular and Neuroscience portfolios, which grew 7% organically each. Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Specialty Therapies were key contributors, with Micra leadless pacemakers and Evolut FX TAVR cited as drivers. Medical Surgical declined 2% organically, or grew 3% excluding ventilator sales and China volume-based procurement (VBP) headwinds. Diabetes grew 3% organically, with strength outside the U.S. offsetting a mid-teens U.S. decline. China VBP tenders and softer procedure volumes in some markets remained the main headwinds. Management raised its full-year fiscal 2023 organic revenue growth outlook and narrowed non-GAAP EPS guidance to $5.28–$5.30 from $5.25–$5.30, with the lower end raised. The guidance includes an estimated $0.21 unfavorable FX impact. For Q4, organic revenue growth is guided to 4.5%–5.0%, and Q4 reported revenue is expected to be hurt by $165–$215 million from FX. The company also reiterated plans to separate its Respiratory Interventions and Patient Monitoring businesses in the second half of fiscal 2024, and to close the contribution of its Renal Care Solutions business into a DaVita-led kidney care company in the fourth fiscal quarter.

Feb 21, 20238-K
Shareholder Matters

Medtronic plc 8-K Report, Shareholder Vote Results (Dec 13, 2022)

This 8-K filing from Medtronic plc details the outcomes of its 2022 Annual General Meeting of Shareholders held on December 8, 2022. The meeting served as a platform for shareholders to vote on key corporate governance matters, including the election of directors, ratification of the independent auditor, executive compensation, and authorities related to share issuance and repurchases. The overall results indicate strong shareholder support for the company's management and proposed actions. Key proposals, including the election of all eleven director nominees and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023, received overwhelming approval. Shareholder approval was also granted for the compensation of named executive officers and for renewing the Board's authority to issue shares, opt out of pre-emption rights, and conduct overseas market purchases of Medtronic ordinary shares. The significant turnout and affirmative votes demonstrate shareholder confidence in Medtronic's leadership and strategic direction.

Dec 13, 20228-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Nov 22, 2022)

Medtronic reported fiscal Q2 2023 (quarter ended October 28, 2022) results that missed management's expectations on the top line. Reported revenue fell 3.3% to $7.585 billion, but organic growth was +2.5% (about +2.2% excluding the $25 million Intersect ENT contribution). Management attributed the shortfall to slower-than-expected recovery in market procedure volumes and supply, plus China volume-based procurement pricing pressure. Growth was led by TAVR (mid-teens), Cardiac Pacing (Micra leadless pacemakers, high-teens), U.S. Core Spine, Specialty Therapies (ENT and Neurovascular), and International Diabetes. Weakness was concentrated in Respiratory, Gastrointestinal & Renal (down 11% organic, with ventilator sales falling sharply) and U.S. Diabetes (down low-double digits). GAAP results were distorted by a $764 million income tax reserve adjustment tied to the U.S. Tax Court opinion on the Puerto Rico income allocation dispute. GAAP diluted EPS was $0.32, down 67% from $0.97. Non-GAAP diluted EPS was $1.30, down 2% from $1.32, and is the more representative measure of underlying profitability. Non-GAAP results were also pressured by inflation in materials, direct labor, freight, and utilities, and by a roughly $0.18 FX headwind in the EPS guidance. Forward guidance was cut. Management now expects fiscal 2023 second-half organic revenue growth of 3.5% to 4.0%, an acceleration from the first half, and fiscal 2023 non-GAAP diluted EPS of $5.25 to $5.30. The FX headwind to revenue was raised to $1.74 to $1.84 billion from $1.4 to $1.5 billion. Management is pursuing expense reductions and organizational streamlining, and it announced portfolio actions including the planned separation of Respiratory Interventions and Patient Monitoring, and the contribution of Renal Care Solutions into a new company with DaVita. Investors should watch whether the second-half acceleration materializes, since that depends on continued procedure and supply recovery.

Nov 22, 20228-K
Material AgreementsRegulation FDOther Events+1

Medtronic plc 8-K Report, Material Agreement (Sep 21, 2022)

Medtronic plc (MDT) announced the closing of a significant debt offering through its indirect wholly owned subsidiary, Medtronic Global Holdings S.C.A. (Medtronic Luxco). The company successfully issued €3.5 billion in aggregate principal amount of senior notes across four tranches with varying maturities and interest rates: 2.625% Senior Notes due 2025, 3.000% Senior Notes due 2028, 3.125% Senior Notes due 2031, and 3.375% Senior Notes due 2034. These notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc. The primary purpose of this offering is to refinance existing debt, specifically Medtronic Luxco's outstanding 0.00% Senior Notes due 2022 and its 0.375% and 0.00% Senior Notes due 2023, which are nearing maturity. The net proceeds, estimated at approximately €3.47 billion after expenses, will also be allocated for general corporate purposes. Medtronic has reiterated that its fiscal year 2023 adjusted earnings per share guidance, previously issued, already accounts for the financial impact of this offering and its use of proceeds. The company has applied to list these new notes on the New York Stock Exchange.

Sep 21, 20228-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Aug 23, 2022)

Medtronic plc reported first quarter fiscal 2023 results (quarter ended July 29, 2022) that beat its own revenue expectations while showing clear pressure from supply chain shortages, COVID-related procedure disruption, and unfavorable foreign currency. Reported revenue was $7.371 billion, down 8% as reported and 4% organically (about 3.6% organic excluding the $20 million Intersect ENT contribution). GAAP diluted EPS rose 25% to $0.70, helped by lower other operating expense, while non-GAAP diluted EPS fell 17% to $1.13, which management described as in line with expectations. Within the portfolio, Medical Surgical was the weakest segment, down 9% organic, driven by ventilator declines and supply constraints in Surgical Innovations. Cardiovascular was down 1% organic, with Cardiac Rhythm & Heart Failure showing leadless pacing strength, and Neuroscience was down 2% organic. Diabetes was flat organically, with U.S. revenue down mid-teens due to a lack of new product approvals offset by international CGM growth. Management reiterated FY23 guidance: organic revenue growth of 4% to 5%, and non-GAAP diluted EPS of $5.53 to $5.65. The FX headwind to revenue has widened to an estimated $1.4 to $1.5 billion, up from $1.0 to $1.1 billion, and EPS carries a 17 to 22 cent FX headwind. The CFO guided to organic growth improving each quarter, with the second half significantly stronger than the first. This guidance depends heavily on a second-half recovery, so investors should watch supply chain normalization and near-term product pipeline catalysts closely. Balance sheet and cash flow were mixed. Free cash flow was $657 million, down from $914 million a year earlier, as operating cash flow fell to $1.083 billion and capital expenditures rose to $426 million. Cash fell to $2.14 billion, and current debt rose to $5.73 billion as the company refinanced maturities. Total debt declined from the prior quarter after roughly $2.3 billion of early debt redemptions, which produced a $53 million loss on extinguishment. The company also completed the Intersect ENT acquisition, which contributed $20 million of revenue in the quarter, and is in the process of selling half of its Renal Care Solutions business to DaVita, which led to goodwill and other impairment charges excluded from non-GAAP results.

Aug 23, 20228-K
Leadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Executive Changes (Jun 27, 2022)

Medtronic plc (NYSE: MDT) filed an 8-K on June 27, 2022 to report a board change: the Board increased its size from 10 to 11 members and appointed Lidia L. Fonseca as an independent director, effective June 27, 2022. The filing is a governance update rather than a financial disclosure, and it contains no earnings, guidance, or capital allocation information. Ms. Fonseca is Executive Vice President and Chief Digital and Technology Officer at Pfizer, with more than 30 years of healthcare innovation experience, including prior CIO roles at Quest Diagnostics and Labcorp. She will serve on the Science and Technology Committee and the Compensation Committee. Under the company's non-employee director compensation policy, she is eligible for an annual cash retainer and a director equity grant, as described in the October 8, 2021 proxy statement. The filing states there are no arrangements tying her selection to any other person and no reportable related-person transactions. For investors, the appointment signals a strategic emphasis on digital health, data, analytics, and AI, consistent with Medtronic's stated goal of becoming the global leader in healthcare technology. The filing does not quantify any cost impact beyond standard director compensation, so the financial effect is expected to be immaterial.

Jun 27, 20228-K
Earnings & ResultsRegulation FDExhibits & Filings

Medtronic plc 8-K Report, Financial Results (May 26, 2022)

Medtronic plc reported fiscal year 2022 (ended April 29, 2022) results alongside a strategic announcement. FY22 revenue rose 5% reported and organically to $31.686 billion, GAAP diluted EPS rose 40% to $3.73, and non-GAAP diluted EPS rose 26% to $5.55 after a recast that removed $0.06 of previously excluded license and acquisition payments. Free cash flow reached $5.978 billion, up 22%, representing 80% conversion of non-GAAP net earnings. Fourth-quarter results were weaker: revenue fell 1% reported but grew 1% organically to $8.089 billion, and non-GAAP EPS of $1.52 rose only 2%. Management attributed the softness to global supply chain constraints and COVID-19 lockdowns in China, and it guided FY23 organic revenue growth of 4% to 5% and non-GAAP EPS of $5.53 to $5.65, with a roughly $1.0 to $1.1 billion currency headwind. The company also raised its quarterly dividend 8% to $0.68 ($2.72 annualized), marking the 45th consecutive annual increase, and reaffirmed a commitment to return at least 50% of free cash flow to shareholders. Separately, Medtronic agreed to contribute its Renal Care Solutions business (about $325 million of FY22 revenue) into a new kidney-care company, NewCo, which it will co-own equally with DaVita. Medtronic expects up to $400 million of value from the transaction, with closing targeted for calendar 2023 and no material expected impact on adjusted EPS. For investors, the key tensions are solid full-year cash generation and a shareholder-friendly dividend versus near-term execution pressure from supply chain and China, a modest FY23 growth outlook, and a portfolio-pruning move that is small relative to the $31.7 billion revenue base.

May 26, 20228-K
Material AgreementsFinancial EventsRegulation FD+1

Medtronic plc 8-K Report, Material Agreement (May 2, 2022)

Medtronic plc (MDT) announced on May 2, 2022, through its subsidiary Medtronic Global Holdings S.C.A., the entry into a 364-day unsecured term loan agreement with Mizuho Bank, Ltd. for up to JPY 300,000,000,000 (approximately $2.3 billion USD based on exchange rates at the time). This facility, which was undrawn at closing, is intended to fund general corporate purposes, specifically the redemption of Medtronic's outstanding $1,900 million 3.500% Senior Notes due 2025 and Medtronic Luxco's $368 million 3.350% Senior Notes due 2027. The company expects these debt refinancing actions to positively impact its fiscal year 2023 interest expense, although this benefit will be partially offset by increased U.S. tax expenses and a generally higher global interest rate environment. Investors should note that the redemption dates for these notes are set for May 17, 2022, and June 1, 2022, respectively. Medtronic plans to provide updated financial guidance for FY2023 during its upcoming Q4 FY2022 earnings call.

May 2, 20228-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Feb 22, 2022)

Medtronic reported third quarter fiscal 2022 results (quarter ended January 28, 2022) that were mixed: reported revenue of $7.763 billion was flat year-over-year and grew 2% organically, while GAAP diluted EPS of $1.10 rose 17% and non-GAAP diluted EPS of $1.37 rose 6%. Management attributed the top-line shortfall primarily to the COVID-19 Omicron resurgence, which peaked in the final weeks of the quarter in January and depressed procedure volumes, particularly in the U.S. Chairman and CEO Geoff Martha said the revenue fell short of company expectations, while CFO Karen Parkhill noted adjusted EPS landed in line with guidance and a penny ahead of consensus. Segment performance was uneven. Cardiovascular grew 3% organically, led by Cardiac Rhythm & Heart Failure (Micra leadless pacemakers, Arctic Front cryoballoons) and TAVR. Surgical Innovations was a bright spot with 9% organic growth, while Respiratory, Gastrointestinal & Renal declined 12% organically as ventilator demand normalized. Neuroscience grew 2% organically, and Diabetes fell 5% organically on high-teens U.S. declines. Geographically, U.S. revenue was flat at $3.939 billion, Non-U.S. Developed was up 1% organically, and Emerging Markets grew 7% organically. Looking ahead, management guided fiscal Q4 organic revenue growth of approximately 5.5%, with a currency headwind of roughly $185 million, and non-GAAP EPS of $1.56 to $1.58. Management expects procedure volumes to recover through March and April and to return to near pre-COVID levels by the end of the fourth quarter. Investors should watch whether that recovery materializes, since the guidance depends heavily on it. Free cash flow for the nine months was $4.31 billion, up from $3.52 billion a year earlier.

Feb 22, 20228-K
Leadership Changes

Medtronic plc 8-K Report, Executive Changes (Dec 16, 2021)

Medtronic plc (MDT) announced the upcoming retirement of Dr. Richard Kuntz, Senior Vice President and Chief Medical and Scientific Officer, effective April 29, 2022. Dr. Kuntz has had a long and distinguished career at Medtronic, serving on the executive committee since 2005, and a significant 40-year career in medicine as an interventional cardiologist. While this filing is primarily administrative, the departure of a long-tenured executive like Dr. Kuntz is noteworthy for investors. His role has been critical in bridging clinical practice with scientific and medical strategy within the company. Investors may wish to monitor the company's succession planning and the strategic direction of its medical and scientific affairs under new leadership.

Dec 16, 20218-K
Regulation FDExhibits & Filings

Medtronic plc 8-K Report, Regulation FD Disclosure (Dec 15, 2021)

On December 15, 2021, Medtronic plc disclosed that it received a warning letter from the U.S. Food and Drug Administration (FDA) on December 9, 2021, following a July 2021 inspection of its Northridge, California facility, which serves as headquarters for its Diabetes business. The letter cites inadequacies in quality system requirements covering risk assessment, corrective and preventive action (CAPA), complaint handling, device recalls, and adverse event reporting. The inspection was tied to recalls of the MiniMed 600 series insulin pump and a remote controller for MiniMed 508 and Paradigm pumps. Medtronic says it is applying company-wide resources and external experts to resolve the observations and is working with the FDA on comprehensive corrective actions. From a financial standpoint, management does not expect the letter to affect total company organic revenue growth or adjusted EPS guidance for fiscal Q3 or full-year fiscal 2022, issued November 23, 2021. However, Diabetes organic revenue expectations were lowered modestly: Diabetes is now expected to decline in the high-single digits in fiscal Q3 (previously mid-single digits) and in the mid-single digits for the full year (previously low-single digits). The company attributes this to uncertainty around the timing of U.S. Diabetes product approvals. Medtronic has modeled a preliminary impact on total company fiscal 2023 revenue growth of less than 0.5 to approximately 1 percentage point, depending on scenarios, and plans to provide full fiscal 2023 guidance on its fiscal Q4 earnings call in May 2022. For investors, the key takeaways are that the near-term consolidated guidance is unchanged, the Diabetes segment faces incremental pressure and approval-timing risk, and the longer-term revenue impact remains uncertain until full guidance is issued. The company also states that no action is recommended for patients or healthcare providers at this time.

Dec 15, 20218-K
Material AgreementsShareholder MattersExhibits & Filings

Medtronic plc 8-K Report, Material Agreement (Dec 14, 2021)

Medtronic plc (MDT) filed an 8-K on December 14, 2021, detailing two key events. The first, under Item 1.01, announces the execution of an amendment to its credit agreement. This amendment extends the maturity date of the credit facility by one year to December 12, 2026, removes limits on future maturity extensions, and updates interest rate benchmarks to reflect the phasing out of LIBOR. Importantly, it also reduces the interest rate margins and commitment fees, making the company's borrowing costs potentially lower. The second significant event, under Item 5.07, covers the outcomes of Medtronic's 2021 Annual General Meeting of Shareholders. Key resolutions passed include the election of all ten director nominees, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation (on an advisory basis). Additionally, shareholders overwhelmingly approved the new 2021 Long Term Incentive Plan, renewed the board's authority to issue shares and opt out of pre-emption rights, and authorized overseas market purchases of company shares. These results indicate strong shareholder support for the company's governance and incentive structures.

Dec 14, 20218-K
Earnings & ResultsExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Nov 23, 2021)

Medtronic plc (NYSE: MDT) reported fiscal Q2 2022 results (quarter ended October 29, 2021) that were solid on earnings but soft on top-line growth. Revenue of $7.847 billion rose 3% as reported and 2% organically, with the COVID-19 resurgence and healthcare staffing shortages depressing procedure volumes, particularly in the U.S., where revenue fell 1% (reported -1.4%). Profitability improved meaningfully: GAAP diluted EPS was $0.97 (up 169%), helped by the absence of prior-year debt tender charges and lower interest expense, while non-GAAP diluted EPS rose 29% to $1.32 and non-GAAP operating margin expanded to 27.0% from 22.3%. Free cash flow for the first half of fiscal 2022 was $2.412 billion, up from $1.524 billion a year earlier. The key forward-looking change is in revenue guidance. Medtronic lowered its fiscal 2022 organic revenue growth outlook to 7-8% from roughly 9%, citing a greater-than-expected pandemic impact that management expects to persist into the second half. Foreign currency is now expected to add only $0-50 million to revenue versus the prior $100-200 million. Management reiterated its fiscal 2022 non-GAAP diluted EPS guidance of $5.65-$5.75, including a 5-10 cent FX benefit, signaling that cost discipline and margin gains are offsetting the revenue shortfall. Segment performance was mixed. Surgical Innovations (+7% organic), Specialty Therapies (+8%), Neuromodulation (+6%), and Cardiac Rhythm & Heart Failure (+6% adjusted for the HVAD discontinuation) were strong, while Respiratory, Gastrointestinal & Renal fell 11% organically on ventilator declines and Cranial & Spinal Technologies was down 1%. Emerging Markets grew 16% organically, a notable offset to U.S. weakness. Investors will likely focus on whether procedure volumes recover in the second half and whether the revised growth outlook proves conservative.

Nov 23, 2021
Page 1 of 3